2023 Fiscal Year Final Research Report
Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer
| Project/Area Number |
19K17153
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52040:Radiological sciences-related
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2024-03-31
|
| Keywords | 子宮頸癌 / 放射線治療 / 高線量率密封小線源治療 / PD-L1 / CD163 / 腫瘍微小環境 |
|---|
| Outline of Final Research Achievements |
This study investigated changes in the immunity of the tumor microenvironment (TME) during standard radical RT for cervical cancer and determined whether these changes affect prognosis. Twenty-six patients who had completed radical RT for cervical cancer were categorized into the following two groups according to whether the cancer recurred and/or metastasized within 2 years after the start of treatment, and we assessed immunohistolical marker between two groups and assessed its effect on prognosis. The expression levels of PD-L1 and CD163 in the TME in the treatment success group were lower than those in the treatment failure group at the midpoint during brachytherapy, and the 2-year progression-free-survival (PFS) rate depended on the expression levels of PD-L1 and CD163. The expression rates of CD163 and PD-L1 in the TME during brachytherapy were related to treatment response and the 2-year PFS.
|
| Free Research Field |
婦人科癌に対する放射線治療
|
| Academic Significance and Societal Importance of the Research Achievements |
子宮頸癌に対する根治的放射線療法において，腫瘍免疫抑制分子の一つであるPD-L1と，腫瘍増大に関わるM2マクロファージの代表マーカーであるCD163に注目した治療法の開発に貢献する結果となった．
|
